Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Impact of SARS-CoV-2 in Hematopoietic Stem Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy Recipients
Muhammad Umair Mushtaq, Moazzam Shahzad, Sibgha Gull Chaudhary, et al.
Transplantation and Cellular Therapy (2021) Vol. 27, Iss. 9, pp. 796.e1-796.e7
Open Access | Times Cited: 53

Showing 1-25 of 53 citing articles:

Poor outcome of patients with COVID-19 after CAR T-cell therapy for B-cell malignancies: results of a multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party and the European Hematology Association (EHA) Lymphoma Group
Anne M. Spanjaart, Per Ljungman, Rafael de la Cámara, et al.
Leukemia (2021) Vol. 35, Iss. 12, pp. 3585-3588
Open Access | Times Cited: 98
Impact of COVID‐19 in hematopoietic stem cell transplant recipients: A systematic review and meta‐analysis
Moazzam Shahzad, Sibgha Gull Chaudhary, Muhammad Usman Zafar, et al.
Transplant Infectious Disease (2022) Vol. 24, Iss. 2
Closed Access | Times Cited: 39
Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry
Alessandro Busca, Jon Salmanton‐García, Francesco Marchesi, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 28
Safety and Immunogenicity After a Three-Dose SARS-CoV-2 Vaccine Schedule in Allogeneic Stem Cell Transplant Recipients
Muneyoshi Kimura, Victor H. Ferreira, Sagar Kothari, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 10, pp. 706.e1-706.e10
Open Access | Times Cited: 35
SARS-CoV-2 vaccination in the first year after allogeneic hematopoietic cell transplant: a prospective, multicentre, observational study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
EClinicalMedicine (2023) Vol. 59, pp. 101983-101983
Open Access | Times Cited: 20
SARS-CoV-2 Vaccination in the First Year After Hematopoietic Cell Transplant or Chimeric Antigen Receptor T-Cell Therapy: A Prospective, Multicenter, Observational Study
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
Clinical Infectious Diseases (2024) Vol. 79, Iss. 2, pp. 542-554
Closed Access | Times Cited: 6
Revised Guidelines for Coronavirus Disease 19 Management in Hematopoietic Cell Transplantation and Cellular Therapy Recipients (August 2022)
M. Veronica Dioverti, Zeinab El Boghdadly, Zainab Shahid, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 12, pp. 810-821
Open Access | Times Cited: 24
High Mortality of COVID-19 Early after Allogeneic Stem Cell Transplantation: A Retrospective Multicenter Analysis on Behalf of the German Cooperative Transplant Study Group
Judith Schaffrath, Christina Brummer, Daniel Wolff, et al.
Transplantation and Cellular Therapy (2022) Vol. 28, Iss. 6, pp. 337.e1-337.e10
Open Access | Times Cited: 22
Outcomes and Management of the SARS-CoV2 Omicron Variant in Recipients of Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T Cell Therapy
María Stefania Infante, David Nemirovsky, Sean M. Devlin, et al.
Transplantation and Cellular Therapy (2023) Vol. 30, Iss. 1, pp. 116.e1-116.e12
Open Access | Times Cited: 12
COVID-19 and HSCT (Hematopoietic stem cell transplant)
Lynne Strasfeld
Best Practice & Research Clinical Haematology (2022) Vol. 35, Iss. 3, pp. 101399-101399
Open Access | Times Cited: 19
Multidisciplinary recommendations for the management of CAR-T recipients in the post-COVID-19 pandemic era
Tingting Zhang, Weiwei Tian, Shuang Wei, et al.
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 10
COVID‐19 after hematopoietic cell transplantation and chimeric antigen receptor (CAR)‐T‐cell therapy
Eleftheria Kampouri, Joshua A. Hill, M. Veronica Dioverti
Transplant Infectious Disease (2023) Vol. 25, Iss. S1
Closed Access | Times Cited: 10
A third dose of mRNA-1273 vaccine improves SARS-CoV-2 immunity in HCT recipients with low antibody response after 2 doses
Elena Pettini, Annalisa Ciabattini, G Pastore, et al.
Blood Advances (2022) Vol. 6, Iss. 7, pp. 2247-2249
Open Access | Times Cited: 15
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
SARS-CoV-2 vaccination in the first year after hematopoietic cell transplant or chimeric antigen receptor T cell therapy: A prospective, multicenter, observational study (BMT CTN 2101)
Joshua A. Hill, Michael J. Martens, Jo‐Anne H. Young, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Treatment-Related Risk Factors for Adverse Outcomes of COVID-19 in Patients Treated for Lymphoid Malignancies in the Pre-Omicron Era—A Study of KroHem, the Croatian Group for Hematologic Diseases
Igor Aurer, Ozren Jakšić, Sandra Bašić‐Kinda, et al.
Biomedicines (2024) Vol. 12, Iss. 2, pp. 331-331
Open Access | Times Cited: 2
Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy
Nausheen Ahmed, Olalekan O. Oluwole, Zahra Mahmoudjafari, et al.
Clinical Hematology International (2024) Vol. 6, Iss. 2
Open Access | Times Cited: 2
COVID-19 in cancer patients
Suranjith L. Seneviratne, Widuranga Wijerathne, Pamodh Yasawardene, et al.
Transactions of the Royal Society of Tropical Medicine and Hygiene (2022) Vol. 116, Iss. 9, pp. 767-797
Open Access | Times Cited: 13
Omicron related COVID-19 prevention and treatment measures for patients with hematological malignancy and strategies for modifying hematologic treatment regimes
Wenjing Guo, Yizhou Zheng, Sizhou Feng
Frontiers in Cellular and Infection Microbiology (2023) Vol. 13
Open Access | Times Cited: 7
COVID‐19 in hematopoietic stem‐cell transplant recipients: A systematic review and meta‐analysis of clinical characteristics and outcomes
Bruno Azevedo Randi, Hermes Ryoiti Higashino, Vinícius Ponzio da Silva, et al.
Reviews in Medical Virology (2023) Vol. 33, Iss. 6
Closed Access | Times Cited: 6
Coronavirus disease 2019 in immunocompromised patients: a comprehensive review of coronavirus disease 2019 in hematopoietic stem cell recipients
Antoine Lafarge, Asma Mabrouki, Elise Yvin, et al.
Current Opinion in Critical Care (2021) Vol. 28, Iss. 1, pp. 83-89
Open Access | Times Cited: 15
Management of Chronic Graft-vs.-Host Disease in Children and Adolescents With ALL: Present Status and Model for a Personalised Management Plan
Agnieszka Sobkowiak-Sobierajska, Caroline A. Lindemans, Tomáš Sýkora, et al.
Frontiers in Pediatrics (2022) Vol. 10
Open Access | Times Cited: 10
Functional SARS-CoV-2-specific T cells of donor origin in allogeneic stem cell transplant recipients of a T-cell-replete infusion: A prospective observational study
Corinna La Rosa, Flavia Chiuppesi, Yoonsuh Park, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 5
Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity
Hoda Pourhassan, Corinna La Rosa, Flavia Chiuppesi, et al.
Blood Advances (2022) Vol. 6, Iss. 6, pp. 1645-1650
Open Access | Times Cited: 9
COVID-19 in patients with acute leukemia: 3 years' experience of pandemic
Т. С. Чуднова, E. N. Misyurina, Е. А. Baryakh, et al.
Oncohematology (2024) Vol. 18, Iss. 4, pp. 45-52
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top